China-based drugmaker CANbridge Pharmaceuticals just reported long-term follow-up data from its Phase I/II study of CAN008 plus temozolomide/radiotherapy (TMZ/RT) in newly diagnosed glioblastoma multiform (GBM) showing a five-year survival rate of 67% compared to 8.2% in the institutional database.